| Bioactivity | PDE4B-IN-3 is a potent PDE4B inhibitor with an IC50 of 0.94 μM. PDE4B-IN-3 has anti-inflammatory activities[1]. | ||||||||||||
| Invitro | PDE4B-IN-3 (compound f4) has good inhibitory activity on the production of NO, TNF-α and IL-1β with IC50 values of 20.40 μM, 23.48 μM, and 18.98 μM in RAW264.7 cells. PDE4B-IN-3 could also inhibit the expression of iNOS and COX-2 in RAW264.7 cells[1]. | ||||||||||||
| In Vivo | In vivo studies shows that PDE4B-IN-3 (compound f4; 10-30 mg/kg) could improve the degree of foot swelling and knee joint pathology in adjuvant-induced arthritic rats and decrease the levels of serum inflammatory factors TNF-α and IL-1β in a dose-dependent manner[1]. | ||||||||||||
| Name | PDE4B-IN-3 | ||||||||||||
| Formula | C30H35N3O4S2 | ||||||||||||
| Molar Mass | 565.75 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Siqi Xing, et al. Novel quinoline-based derivatives: A new class of PDE4B inhibitors for adjuvant-induced arthritis. Eur J Med Chem. 2022 Aug 5;238:114497. |